Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia

NCT04241705 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

48960

Enrollment

OTHER

Sponsor class

Conditions

Malaria

Interventions

OTHER: Treatment of positive individuals per national treatment guidelines
OTHER: Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)
OTHER: Optimized malaria control interventions

Sponsor

Armauer Hansen Research Institute, Ethiopia

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]